You are here:
Dear Doctor Letter (Rote-Hand-Brief) on darunavir/cobicistat: increased risk of therapeutic failure and mother-to-child transmission of HIV
2018.06.25
Active substance: darunavir, cobicistat
The company Janssen-Cilag GmbH is circulating information on the fact that treatment with darunavir/cobicistat should not be initiated during pregnancy.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN